3-Bromo-1-adamantanecarboxylic Acid: A Key Intermediate for Pharmaceutical Innovation

Discover the critical role of 3-Bromo-1-adamantanecarboxylic Acid (CAS: 21816-08-0) in advancing drug discovery. As a leading manufacturer and supplier in China, we provide high-purity intermediates essential for developing next-generation pharmaceuticals, offering unparalleled quality and competitive pricing.

Get a Quote & Sample

Key Advantages of Partnering With Us

Unmatched Purity & Consistency

Our commitment to quality ensures that every batch of 3-bromo-1-adamantanecarboxylic acid (CAS: 21816-08-0) meets stringent purity standards (≥98%), crucial for reproducible research and successful API synthesis. Partner with a manufacturer you can trust.

Cost-Effective Pharmaceutical Sourcing

As a direct supplier in China, we offer competitive pricing for 3-bromo-1-adamantanecarboxylic acid, making high-quality intermediates accessible for your budget. Inquire for a quote today.

Expertise in Organic Synthesis

Leverage our deep understanding of organic chemistry. We provide essential building blocks like 3-bromo-1-adamantanecarboxylic acid to facilitate breakthroughs in drug discovery, especially in areas like MDR reversal agents.

Core Application Areas

Pharmaceutical Synthesis

Utilize our 3-bromo-1-adamantanecarboxylic acid as a critical building block in the synthesis of complex pharmaceutical intermediates and APIs, enabling the creation of novel therapeutic agents.

MDR Reversal Agents

Research and develop potent multidrug resistance (MDR) reversal agents by incorporating adamantyl derivatives synthesized from this key intermediate, vital for enhancing cancer chemotherapy efficacy.

Organic Chemistry Research

Employ 3-bromo-1-adamantanecarboxylic acid in advanced organic synthesis projects, exploring new molecular structures and their potential applications across various scientific disciplines.

Anticancer Drug Development

Source this intermediate to accelerate your R&D efforts in developing innovative anticancer drugs, focusing on overcoming drug resistance and improving patient outcomes.